BACKGROUND: With more than 460 RHD alleles, this gene is the most complex and polymorphic among all blood group systems. The Tunisian population has the largest known prevalence of weak D Type 4.0 alleles, occurring in one of 105 RH haplotypes. We aimed to establish a rationale for the transfusion strategy of weak D Type 4.0 in Tunisia.
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BACKGROUND: With more than 460 RHD alleles, this gene is the most complex and polymorphic among all blood group systems. The Tunisian population has the largest known prevalence of weak D Type 4.0 alleles, occurring in one of 105 RH haplotypes. We aimed to establish a rationale for the transfusion strategy of weak D Type 4.0 in Tunisia.
STUDY DESIGN AND METHODS: Donors were
randomly screened for the serologic weak D phenotype. The RHD coding sequence and parts of the introns were sequenced. To establish the RH haplotype, the RHCE gene was tested for characteristic single-nucleotide positions.
RESULTS:
We determined all RHD alleles and the RH 
CONCLUSIONS: Among the weak D phenotypes in
Tunisia, no novel RHD allele was found and almost 90% were caused by alleles of the weak D Type 4 cluster, of which 88% represented the weak D Type 4.0 allele. Based on established RH haplotypes for variant RHD and RHCE alleles and the lack of adverse clinical reports, we recommend D1 transfusions for patients with weak D Type 4.0 in Tunisia. R h, encoded by the RHD and RHCE genes, is the most complex and polymorphic blood group system in humans. Apart from ABO, 1 26 or less in Europe. 27 A systematic study was missing for samples with the serologic weak D phenotype routinely found in blood donor and patient testing in Tunisia. We tested a cohort of 13,431 Tunisian blood donations, identified all samples with a serologic weak D phenotype, and sequenced their RHD genes. Characteristic single-nucleotide polymorphisms (SNPs) were also determined to ascertain the RHCE allele linked to the known RHD allele, thus constituting RH haplotypes.
MATERIALS AND METHODS

Study subjects
EDTA-anticoagulated whole blood samples from 13 (Table S1, 
RBC genotyping
The RHD gene was sequenced in all samples with serologic weak D phenotype and the RHCE gene in select samples as described previously.
27,29
The nucleotide sequences of all 10 exons as well as the adjacent intronic regions including the 5 0 and 3 0 untranslated regions (UTRs) were determined. Zygosity testing for the RHD gene was done by quantitative fluorescence polymerase chain reaction (PCR) using RHD Intron 4 24 and RHCE Exon 7 (two-copy internal control) as described previously. 30 For screening of the RHCE gene, characteristic SNPs were determined (RHCE BeadChip Kit, BioArray Solutions), 31 which cannot detect RHCE*ceAG recently described in African Americans. 32 Nucleotide sequences were aligned and compared to reference sequences as described previously. 33 When sequencing of RHD Exons 5 or 6 or both failed in five samples-there was no amplification because of presumably low DNA quality-we were, however, able to confirm the positions 602 (T201R) and 667 (F223V) by PCR with sequence-specific priming 12, 18 
Statistical analysis
The 95% confidence interval (CI) for allele frequencies was calculated based on the Poisson distribution using a Web resource. The DVII allele frequency in Southwestern Germany was calculated from the observed phenotype frequency. 34 
RESULTS
Using blood center routine methods, we screened 13,431 blood donations in Tunisia for the D antigen, 11,974 of whom were found D1 (89.15%) and 1390 D-(10.35%). The serologic weak D phenotype was observed in 67 distinct donors (0.50%). They were sorted based on the anti-D agglutination strength in the three routine techniques, and 47 of them were also tested with a panel of six monoclonal anti-D reagents (Table S1 ). Although multiple serologic routine methods were applied, a discrimination of D variant was impossible by serology alone.
RHD alleles
We determined the full length RHD coding sequence in all 67 samples (Table 1) . Among them, 60 carried an allele of the weak D Type 4 cluster (89.6%), of which 53 samples (88.3%) showed the weak D Type 4.0 allele. We deposited three representative alleles (GenBank Accession No. KY075647 to KY075649) including 106 nucleotides of the 5 0 UTR and at least 126 nucleotides of the 3 0 UTR for a total of at least 5019 nucleotides of RHD gene (Table 1) . Only one sample each was found for the weak D Types 1, 3, and 100 and the DVII, while three samples showed the consensus RHD sequence, all compatible with published GenBank data ( Table 1) .
Comparing allele frequencies with previous Tunisian cohorts
The weak D Type 4.0 was the most prevalent molecular weak D type in Tunisians, confirming our previously published data. 12 Comparing our current data ( (Table S1) . Without molecular data, at least one weak D Type 4.2 carrier would have been assigned as D1 for transfusions (Table S1 ). 
RHCE alleles
All 67 samples were tested for characteristic SNPs by a DNA bead platform. The RHCE Exons 1, 5, and 7, harboring diagnostic SNPs, were sequenced in all 53 weak D Type 4.0 samples and included in the GenBank submissions (KY075647 to KY075649), indicating the RH haplotypes. We tabulated the concordance between distinct RHD alleles and distinct RHCE alleles along with the frequency of RH haplotypes formed by such RHD-RHCE linkage disequilibrium in the population (Table 3 ). All Rh phenotypes (CcDEe) observed were compatible with the prediction derived from RBC genotyping of the involved RHCE alleles.
DVII alleles
The greatest prevalence of DVII alleles had been reported in the German population. Comparing published data (Table S2 , available as supporting information in the online version of this paper), 19, 34, 36 we found that the DVII allele may be more common in the Tunisian (0.4%) than the German population (0.13%). This difference was significant (p < 0.001, v 2 5 19.94, two-sided).
DISCUSSION
The prevalences of the common weak D Types 1, 2, 3, 4, 5, and 11 alleles had been tested molecularly among 2000 random blood donors in Tunisia including D1 and Dindividuals. 18 Here we identified all samples with a serologic weak D phenotype in a cohort of 13,431 Tunisian blood donations, sequenced their RHD genes, and established the RH haplotypes. The study was designed to obtain data on weak D Type 4.0 in a population known to harbor the greatest prevalence of such allele worldwide. 12, 18 Recently, a work group 4 identified the need for more data for weak D Types 4.0 or 4.1, 4 the topic of this research.
Only two samples found by our screen for the serologic weak D phenotype represented weak D Types 1 and 3 (Table 1) , which are much more common in Caucasians. Because we performed molecular genotyping only in cases with serologic weak D phenotype, the true prevalence of D variants in the Tunisian population certainly exceeds 0.50%. An estimated 24 of 77 Tunisian individuals (31% ,  Table 2 ) expressing the weak D Type 4.0 phenotype have routinely been typed as D1 and would eventually be transfused with D1 blood and not receive RhIG in case of pregnancies. No adverse clinical effect has been documented in Tunisia, except one observation of an autoanti-D. and no additional examples have been published since. Based on our previous studies 12 and the current data (Table 2) , along with the lack of any observed substantial adverse clinical effect, 13 we conclude that patients and pregnant women in Tunisia expressing weak D Type 4.0 phenotype should be treated as D1 and should not be exposed to RhIG, from which these women or their babies cannot be expected to benefit clinically. We propose this strategy as a pragmatic clinical decision in the light of current evidence. If eventually a rare alloanti-D immunization should occur, a revised strategy may be considered in Tunisia, depending on the frequency, the clinical relevance, and the cost to detect and manage weak D 43 Hence, the associated RHCE alleles differed to some extent depending on the population studied.
There is a possibility that the RHCE*ceVS.04.01 allele, typically associated in Tunisian individuals (Table 3) , may protect from alloanti-D immunization, while other RHCE alleles, such as the RHCE*ce more often associated in individuals of other ethnic groups, may not. This conjecture, supported by not much evidence, would need corroboration by experimental and clinical data before it could be used to guide clinical recommendations.
The weak D Type 100 observed in our study was associated with an RHCE*ce allele (Table 3) while it had previously been reported with an RHCE*Ce allele. 44 The serologic weak D phenotype in three samples (Table 1) without any RHD coding exon mutation may be explained by the suppressive effect of the RHCE*Ce allele in trans. We observed only one donor with a DVII allele among the serologic weak D phenotypes, while the DVII allele was shown to be more common (Table S2) in the Tunisian (0.4%) 19 than even the German population (0.13%). 34 Similar to weak D Type 4.0, most DVII were likely typed as normal D, not having a serologic weak D phenotype. We regularly and unknowingly transfuse most patients carrying the DVII, a partial D, with D1 blood. 45 No precautions to detect DVII have ever been mandated, although Dtransfusions would be recommended in any patient, especially women of childbearing age, known to express DVII, as carriers of this partial D can make anti-D. The study exemplified that D variants cannot reliably be discriminated with serologic methods (Table S1) 46-48 using samples from the Arab population, which has been characterized by serology and molecular techniques before (see supporting information). [49] [50] [51] [52] [53] No novel RHD allele was found in our study among 67 donors with the serologic weak D phenotype. We conclude that the molecular description of RHD alleles may have become rather complete, even for complex and variable alleles, such as represented by the RHD alleles constituting the weak D Type 4 cluster. 54 While weak D Type 4.0 is the most prevalent weak D type in Tunisia ( 28 
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